Oncternal Therapeutics In... (ONCT)
NASDAQ: ONCT
· Real-Time Price · USD
0.53
-0.16 (-23.63%)
At close: Dec 02, 2024, 10:00 PM
Oncternal Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 1.67M | 1.85M | 1.15M | 582K | 456K | 659K | 744K | 1.49M | 1.88M | 3.62M | 4.31M | 4.32M | 5.35M | 3.8M | 3.54M |
Cost of Revenue | 18.63M | 18.7M | 12.84M | 6.78M | 147K | 107K | 135K | 179K | 3.84M | 12.77M | 17.9M | 21.77M | 21.05M | 15.14M | 13.76M |
Gross Profit | -16.96M | -16.86M | -11.69M | -6.2M | 309K | 552K | 609K | 1.31M | -1.97M | -9.15M | -13.59M | -17.45M | -15.71M | -11.33M | -10.22M |
Operating Income | -35.96M | -37.67M | -38.35M | -41.71M | -43.99M | -44.93M | -47.18M | -44.93M | -41.1M | -39.41M | -35.3M | -31.37M | -26.15M | -20.91M | -18.75M |
Interest Income | 1.38M | 1.7M | 1.97M | 2.23M | 2.28M | 1.95M | 1.43M | 777K | 269K | 76K | 30K | 33K | 29K | 22K | 14K |
Pretax Income | -34.58M | -35.97M | -36.38M | -39.48M | -41.72M | -42.98M | -45.75M | -44.17M | -40.84M | -39.35M | -35.29M | -31.33M | -25.82M | -20.58M | -18.44M |
Net Income | -34.58M | -35.97M | -36.38M | -39.48M | -41.2M | -42.06M | -44.73M | -43.13M | -40.32M | -39.22M | -35.27M | -31.33M | -25.82M | -20.58M | -18.44M |
Selling & General & Admin | 12.33M | 12.7M | 12.72M | 12.75M | 12.77M | 12.94M | 13.09M | 13.46M | 12.79M | 12.32M | 12.48M | 11.6M | 10.44M | 9.57M | 8.53M |
Research & Development | 25.79M | 26.82M | 26.78M | 29.75M | 31.88M | 32.85M | 35.03M | 32.98M | 30.2M | 30.72M | 27.15M | 24.09M | 21.05M | 15.14M | 13.76M |
Other Expenses | -6.19M | -5.7M | 203K | n/a | -374K | -756K | -947K | -1.49M | -1.32M | -937K | -746K | n/a | 301K | 301K | 301K |
Operating Expenses | 37.63M | 39.34M | 39.22M | 42.01M | 43.99M | 44.93M | 47.18M | 44.95M | 41.11M | 39.42M | 35.32M | 31.37M | 26.15M | 20.91M | 18.75M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 38.12M | 39.34M | 39.22M | 42.01M | 43.99M | 44.93M | 47.18M | 44.95M | 41.11M | 39.42M | 35.32M | 31.37M | 26.15M | 20.91M | 18.75M |
Income Tax Expense | n/a | -75K | -112K | -112K | -627K | -952K | -1.02M | -1.04M | -531K | -174K | -108K | -132K | -2.99M | -2.95M | -2.9M |
Shares Outstanding (Basic) | 2.96M | 2.96M | 2.96M | 2.95M | 2.95M | 2.94M | 2.93M | 2.83M | 16.11M | 16.11M | 16.11M | 16.11M | 16.11M | 16.11M | 16.11M |
Shares Outstanding (Diluted) | 2.96M | 2.96M | 2.96M | 2.95M | 2.95M | 2.94M | 2.93M | 2.83M | 16.11M | 16.11M | 16.11M | 16.11M | 16.11M | 16.11M | 16.11M |
EPS (Basic) | -11.69 | -12.18 | -12.34 | -13.44 | -14.18 | -11.5 | -9.17 | -5.85 | -2.5 | -2.43 | -2.19 | -1.95 | -1.54 | -1.16 | -1.02 |
EPS (Diluted) | -11.69 | -12.18 | -12.34 | -13.44 | -14.18 | -11.5 | -9.17 | -5.85 | -2.5 | -2.43 | -2.19 | -1.95 | -1.54 | -1.16 | -1.02 |
EBITDA | -26.74M | -28.45M | -29.13M | -41.27M | -44.21M | -45.15M | -47.4M | -45.16M | -41.11M | -39.42M | -35.32M | -31.37M | -26.15M | -20.91M | -18.75M |
EBIT | -35.96M | -37.67M | -38.35M | -41.71M | -43.99M | -44.93M | -47.18M | -44.95M | -41.11M | -39.42M | -35.32M | -31.37M | -26.15M | -20.91M | -18.75M |
Depreciation & Amortization | 27.28M | 27.35M | 18.53M | 9.75M | 147K | 107K | 135K | 179K | 188K | 196K | 173K | 169K | 2.99M | 7.34M | 12.83M |